Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

Area of Science:

• Oncology
• Pharmacology

Background:

• Lung carcinoma is a leading cause of cancer death globally.
• Many patients experience disease progression after first-line chemotherapy, necessitating novel second-line treatments.
• Antiangiogenic agents are emerging as crucial therapeutic targets in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To review preclinical and clinical evidence supporting nintedanib's efficacy in NSCLC.
• To highlight the role of nintedanib as a second-line treatment option.

Main Methods:

• Review of preclinical studies investigating nintedanib's anticancer activity.
• Analysis of clinical trial data, including the phase III LUME-Lung 1 trial, evaluating nintedanib in combination therapy.
• Focus on nintedanib's mechanism of action as a tyrosine kinase inhibitor targeting angiogenesis-related receptors.

Main Results:

• Nintedanib targets vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors.
• The phase III LUME-Lung 1 trial demonstrated significant overall survival improvement when nintedanib was combined with docetaxel for second-line treatment in advanced NSCLC.
• Nintedanib exhibited a manageable safety profile in clinical studies.

Conclusions:

• Nintedanib, in combination with docetaxel, represents an approved and effective second-line therapy for advanced NSCLC in Europe.
• The antiangiogenic properties of nintedanib offer a valuable therapeutic strategy for lung cancer treatment.
• Further research and clinical application of nintedanib are warranted for NSCLC management.